The Decipher genomic test could help doctors decide which high-risk prostate cancer patients need abiraterone hormone therapy ...

Three phase 3 prostate cancer results from ESMO 2026 cover long-term survival with abiraterone in metastatic disease, Erleada before and after surgery, and an update on Truqap for PTEN-deficient ...

Adding darolutamide to standard treatment for aggressive prostate cancer reduced the risk of the disease spreading in an ...

Over the last 15 years, low-risk prostate cancer has become less common at diagnosis and is increasingly managed through active surveillance, according to research published in Ca ...

The diagnosis and treatment of low-risk prostate cancer has changed in recent years. | Diagnostics And Laboratory Medicine ...

UChicago researchers identify a previously unknown RNA molecule that allows prostate cancer cells to escape targeted ...

Risk factors are things that raise your chances of getting a disease. For each person, there’s a mix of genetic, biological and lifestyle factors that play a part in prostate cancer risk. About 1 in ...

With an expected 333,830 new cases in 2026, prostate cancer remains the most common malignancy in men in the United States.  ...

Every so often there is an urgent call for a national prostate cancer screening program to be introduced, usually following the diagnosis of a high-profile person with the disease. Prostate cancer is ...

Explore integrative therapies for metastatic prostate cancer, including nutrition, acupuncture, supplements, exercise, and ...